Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts

References

• Uhlmann R. F., Larson E. B., Koepsell T. D., Rees T. S., Duckert L. G. Visual impairment and cognitive dysfunction in Alzheimer's disease. J Gen Intern Med 1991; 6: 126–32
   PubMed Web of Science ®Google Scholar
• Lin M. Y., Gutierrez P. R., Stone K. L., Yaffe K., Ensrud K. E., Fink H. A., et al. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc 2004; 52: 1996–2002
   PubMed Web of Science ®Google Scholar
• Rovner B. W., Casten R. J., Tasman W. S. Effect of depression on vision function in age‐related macular degeneration. Arch Ophthalmol 2002; 120: 1041–4
   PubMed Web of Science ®Google Scholar
• Abyad A. In‐office screening for age‐related hearing and vision loss. Geriatrics 1997; 52: 45–6; 51–4; 57
   Google Scholar
• Berman K., Brodaty H. Psychosocial effects of age‐related macular degeneration. Int Psychogeriatr 2006; 8: 1–14
   Google Scholar
• Taylor H., Guymer R., Keeffe J. The Impact of Age‐Related Macular Degeneration. University of Melbourne, Melbourne 2006; 1–72, Access Economics Pty Limited
   Google Scholar
• Sunness J. S. The natural history of geographic atrophy, the advanced atrophic form of age‐related macular degeneration. Mol Vis 1999; 5: 25
   PubMedGoogle Scholar
• Magnitude and causes of visual impairment. World Health Organization, Fact Sheet No 282.
   Google Scholar
• Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G. P., et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844–51
   PubMed Web of Science ®Google Scholar
• Klein R., Peto T., Bird A., Vannewkirk M. R. The epidemiology of age‐related macular degeneration. Am J Ophthalmol 2004; 137: 486–95
   PubMed Web of Science ®Google Scholar
• Smith W., Assink J., Klein R., Mitchell P., Klaver C., Klein B., et al. Risk factors for age‐related macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108: 697–704
   PubMed Web of Science ®Google Scholar
• Mitchell P., Smith W., Attebo K., Wang J. Prevalence of age‐related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450–60
   PubMed Web of Science ®Google Scholar
• VanNewkirk M., Nanjan M., Wang J., Mitchell P., Taylor H., McCarty C. The prevalence of age‐related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593–600
   PubMed Web of Science ®Google Scholar
• Wolfs R. C., Borger P. H., Ramrattan R. S., Klaver C. C., Hulsman C. A., Hofman A., et al. Changing views on open‐angle glaucoma: definitions and prevalences—The Rotterdam Study. Invest Ophthalmol Vis Sci 2000; 41: 3309–21
   PubMed Web of Science ®Google Scholar
• Mitchell P., Wang J. J., Foran S., Smith W. Five‐year incidence of age‐related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 2002; 109: 1092–7
   PubMed Web of Science ®Google Scholar
• Friedman D. S., O'Colmain B. J., Munoz B., Tomany S. C., McCarty C., de Jong P. T., et al. Prevalence of age‐related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564–72
   PubMed Web of Science ®Google Scholar
• Taylor H. R., Keeffe J. E., Vu H. T., Wang J. J., Rochtchina E., Pezzullo M. L., et al. Vision loss in Australia. Med J Aust 2005; 182: 565–8
   PubMed Web of Science ®Google Scholar
• Jonasson F., Arnarsson A., Peto T., Sasaki H., Sasaki K., Bird A. C. 5‐year incidence of age‐related maculopathy in the Reykjavik Eye Study. Ophthalmology 2005; 112: 132–8
   Google Scholar
• Andersen N. Age‐related macular degeneration among the Inuit in Greenland. Int J Circumpolar Health 2004; 63(Suppl 2)320–3
   Google Scholar
• Vingerling J. R., Dielemans I., Hofman A., Grobbee D. E., Hijmering M., Kramer C. F., et al. The prevalence of age‐related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205–10
   PubMed Web of Science ®Google Scholar
• Krishnaiah S., Das T., Nirmalan P. K., Nutheti R., Shamanna B. R., Rao G. N., et al. Risk factors for age‐related macular degeneration: findings from the Andhra Pradesh eye disease study in South India. Invest Ophthalmol Vis Sci 2005; 46: 4442–9
   PubMed Web of Science ®Google Scholar
• Munoz B., Klein R., Rodriguez J., Snyder R., West S. K. Prevalence of age‐related macular degeneration in a population‐based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol 2005; 123: 1575–80
   PubMedGoogle Scholar
• Leske M. C., Wu S. Y., Hennis A., Nemesure B., Yang L., Hyman L., et al. Nine‐year incidence of age‐related macular degeneration in the Barbados Eye Studies. Ophthalmology 2006; 113: 29–35
   PubMed Web of Science ®Google Scholar
• Wong T. Y., Loon S. C., Saw S. M. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol 2006; 90: 506–11
   PubMed Web of Science ®Google Scholar
• Klein R., Davis M. D., Magli Y. L., Segal P., Klein B. E., Hubbard L. The Wisconsin age‐related maculopathy grading system. Ophthalmology 1991; 98: 1128–34
   PubMed Web of Science ®Google Scholar
• Age‐Related Eye Disease Study Research Group. The Age‐Related Eye Disease Study (AREDS): design implications. AREDS report no. 1., Control Clin Trials. 20. 573–600
   Google Scholar
• Davis M. D., Gangnon R. E., Lee L. Y., Hubbard L. D., Klein B. E., Klein R., et al. The Age‐Related Eye Disease Study severity scale for age‐related macular degeneration: AREDS Report No.17. Arch Ophthalmol 2005; 123: 1484–98
   PubMed Web of Science ®Google Scholar
• Ferris F. L., Davis M. D., Clemons T. E., Lee L. Y., Chew E. Y., Lindblad A. S., et al. A simplified severity scale for age‐related macular degeneration: AREDS Report No.18. Arch Ophthalmol 2005; 123: 1570–4
   PubMed Web of Science ®Google Scholar
• Wray S., Kuwabara T., Sanderson P. Menkes' kinky hair disease: a light and electron microscopic study of the eye. Invest Ophthalmol 1976; 15: 128–38
   Google Scholar
• Abugreen S., Muldrew K. A., Stevenson M. R., VanLeeuwen R., DeJong P. T., Chakravarthy U. CNV subtype in first eyes predicts severity of ARM in fellow eyes. Br J Ophthalmol 2003; 87: 307–11
   Google Scholar
• Clemons T. E., Milton R. C., Klein R., Seddon J. M., Ferris F. L., 3rd. Risk factors for the incidence of Advanced Age‐Related Macular Degeneration in the Age‐Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112: 533–9
   PubMed Web of Science ®Google Scholar
• Thornton J., Edwards R., Mitchell P., Harrison R. A., Buchan I., Kelly S. P. Smoking and age‐related macular degeneration: a review of association. Eye 2005; 19: 935–44
   PubMed Web of Science ®Google Scholar
• Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417–36
   PubMed Web of Science ®Google Scholar
• Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial, The Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998; 105: 1364–72
   Google Scholar
• Complications of Age‐Related Macular Degeneration Prevention Trial Study Group. The Complications of Age‐Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 2004; 1: 91–107
   Google Scholar
• Friberg T. R., Musch D. C., Lim J. I., Morse L., Freeman W., Sinclair S. Prophylactic treatment of age‐related macular degeneration report number 1: 810‐nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 2006; 113: 622 e1
   PubMed Web of Science ®Google Scholar
• Prenner J. L., Rosenblatt B. J., Tolentino M. J., Ying G. S., Javornik N. B., Maguire M. G., et al. Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina 2003; 23: 307–14
   Google Scholar
• Friberg T. R., the PTAMD Study Group. The Prophylactic Treatment of AMD Multi‐Centered Trial (PTAMD): Results From the Bilateral Study Arm. Invest Ophthalmol Vis Sci 2006; 47, E‐Abstract 3538
   Google Scholar
• Argon laser photocoagulation for neovascular maculopathy, Three‐year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986; 104: 694–701
   PubMed Web of Science ®Google Scholar
• Krypton laser photocoagulation for neovascular lesions of age‐related macular degeneration, Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1990; 108: 816–24
   PubMed Web of Science ®Google Scholar
• Laser photocoagulation of subfoveal neovascular lesions in age‐related macular degeneration, Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109: 1220–31
   PubMed Web of Science ®Google Scholar
• Han D. P., Folk J. C., Bratton A. R. Visual loss after successful photocoagulation of choroidal neovascularization. Ophthalmology 1988; 95: 1380–4
   Google Scholar
• Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age‐related macular degeneration, Macular Photocoagulation Study Group. Arch Ophthalmol 1990; 108: 825–31
   PubMed Web of Science ®Google Scholar
• Freund K. B., Yannuzzi L. A., Sorenson J. A. Age‐related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993; 115: 786–91
   PubMed Web of Science ®Google Scholar
• Bressler N. M., Bressler S. B., Childs A. L., Haller J. A., Hawkins B. S., Lewis H., et al. Surgery for hemorrhagic choroidal neovascular lesions of age‐related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111: 1993–2006
   PubMed Web of Science ®Google Scholar
• Hawkins B. S., Bressler N. M., Miskala P. H., Bressler S. B., Holekamp N. M., Marsh M. J., et al. Surgery for subfoveal choroidal neovascularization in age‐related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004; 111: 1967–80
   PubMed Web of Science ®Google Scholar
• Machemer R., Steinhorst U. H. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age‐related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993; 231: 635–41
   Google Scholar
• de Juan E., Jr., Loewenstein A., Bressler N. M., Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol 1998; 125: 635–46
   PubMed Web of Science ®Google Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age‐related macular degeneration with verteporfin: one‐year results of 2 randomized clinical trials—TAP report. Treatment of age‐related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329–45
   PubMed Web of Science ®Google Scholar
• Schmidt‐Erfurth U., Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age‐related macular degeneration. Surv Ophthalmol 2000; 45: 195–214
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age‐related macular degeneration: two‐year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–60
   PubMed Web of Science ®Google Scholar
• Bressler N. M., Arnold J., Benchaboune M., Blumenkranz M. S., Fish G. E., Gragoudas E. S., et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age‐related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes—TAP report No.3. Arch Ophthalmol 2002; 120: 1443–54
   PubMedGoogle Scholar
• Stevenson M. R., Hart P. M., Chakravarthy U., Mackenzie G., Bird A. C., Owens S. L., et al. Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS report 2. Br J Ophthalmol 2005; 89: 1045–51
   PubMed Web of Science ®Google Scholar
• Goverdhan S. V., Gibbs F. A., Lotery A. J. Radiotherapy for age‐related macular degeneration: no more pilot studies please. Eye 2005; 19: 1137–41
   Google Scholar
• Marcus D. M., Peskin E., Maguire M., Weissgold D., Alexander J., Fine S., et al. The age‐related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004; 138: 818–28
   PubMed Web of Science ®Google Scholar
• Gragoudas E. S., Adamis A. P., Cunningham E. T., Jr., Feinsod M., Guyer D. R. Pegaptanib for neovascular age‐related macular degeneration. N Engl J Med 2004 30; 351: 2805–16
   PubMed Web of Science ®Google Scholar
• Heier JS., Shapiro H., Singh AA. Randomized, Controlled Phase III Study of Ranibizumab (LucentisTM) for Minimally Classic or Occult Neovascular Age‐Related Macular Degeneration: Two‐Year Efficacy Results of the MARINA Study. Invest Ophthalmol Vis Sci 2006; 47, E‐Abstract 2959
   Google Scholar
• Rosenfeld P. J., Moshfeghi A. A., Puliafito C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age‐related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331–5
   PubMed Web of Science ®Google Scholar
• Avery R. L., Pieramici D. J., Rabena M. D., Castellarin A. A., Nasir M. A., Giust M. J. Intravitreal bevacizumab (Avastin) for neovascular age‐related macular degeneration. Ophthalmology 2006; 113: 363–72 e5
   PubMed Web of Science ®Google Scholar
• Vinores S. A. Anecortave (Alcon Laboratories). IDrugs 2005; 8: 327–34
   Google Scholar
• D'Amico D. J., Goldberg M. F., Hudson H., Jerdan J. A., Krueger D. S., Luna S. P., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age‐related macular degeneration: twelve‐month clinical outcomes. Ophthalmology 2003; 110: 2372–83, discussion 84–5
   PubMed Web of Science ®Google Scholar
• Spaide R. F., Sorenson J., Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301–4
   PubMed Web of Science ®Google Scholar
• Quiram P. A., Gonzales C. R., Schwartz S. D. Severe steroid‐induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006; 141: 580–2
   PubMed Web of Science ®Google Scholar
• Jonas J. B., Kreissig I., Spandau U. H., Harder B. Infectious and noninfectious endophthalmitis after intravitreal high‐dosage triamcinolone acetonide. Am J Ophthalmol 2006; 141: 579–80
   PubMed Web of Science ®Google Scholar
• Guymer R. H., Chiu A. W., Lim L., Baird P. N. HMG CoA reductase inhibitors (statins): do they have a role in age‐related macular degeneration?. Surv Ophthalmol 2005; 50: 194–206
   PubMed Web of Science ®Google Scholar
• Sarks S., Arnold J., Killingsworth M., Sarks J. Early drusen formation in the normal and aging eye and their relation to age‐related maculopathy: a clinicopathological study. Br J Ophthalmol 1999; 83: 358–68
   PubMed Web of Science ®Google Scholar
• McConnell V., Silvestri G. Age‐related macular degeneration. Ulster Med J 2005; 74: 82–92
   PubMedGoogle Scholar
• Provis J. M., Penfold P. L., Cornish E. E., Sandercoe T. M., Madigan M. C. Anatomy and development of the macula: specialisation and the vulnerability to macular degeneration. Clin Exp Optom 2005; 88: 269–81
   PubMedGoogle Scholar
• Donoso L. A., Kim D., Frost A., Callahan A., Hageman G. The role of inflammation in the pathogenesis of age‐related macular degeneration. Surv Ophthalmol 2006; 51: 137–52
   PubMed Web of Science ®Google Scholar
• Arnold J., Sarks S. Age related macular degeneration. Clin Evid 2004; 819–34
   Google Scholar
• Hageman G., Mullins R. Molecular composition of drusen as related to substructural phenotype. Mol Vis 1999; 5: 28
   PubMed Web of Science ®Google Scholar
• Sarraf D., Gin T., Yu F., Brannon A., Owens S. L., Bird A. C. Long‐term drusen study. Retina 1999; 19: 513–9
   Google Scholar
• Klein R., Klein B., Jensen S., Meuer S. The five‐year incidence and progression of age‐related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104: 7–21
   PubMed Web of Science ®Google Scholar
• Spraul C., Grossniklaus H. Characteristics of drusen and Bruch's membrane in postmortem eyes with age‐related macular degeneration. Arch Ophthalmol 1997; 115: 267–73
   PubMed Web of Science ®Google Scholar
• Sarks J. P., Sarks S. H., Killingsworth M. C. Evolution of soft drusen in age‐related macular degeneration. Eye 1994; 8((Pt 3))269–83
   Google Scholar
• Guymer R., Bird A. Bruch's membrane, drusen, and age‐related macular degeneration. The Retinal Pigment Epithelium, M Marmor, T Wolfensberger. Oxford University Press, New York 1998; 693–705
   Google Scholar
• Zarbin M. A. Current concepts in the pathogenesis of age‐related macular degeneration. Arch Ophthalmol 2004 Apr; 122: 598–614
   PubMed Web of Science ®Google Scholar
• Sivaprasad S., Bailey T. A., Chong V. N. Bruch's membrane and the vascular intima: is there a common basis for age‐related changes and disease?. Clin Experiment Ophthalmol 2005; 33: 518–23
   PubMedGoogle Scholar
• Marshall J., Hussain A., Starita C., Moore D., Patmore A. The Retinal Pigment Epithelium. Oxford University Press, New York 1998
   Google Scholar
• Guymer R., Luthert P., Bird A. Changes in Bruch's membrane and related structures with age. Prog Retin Eye Res 1999; 18: 59–90
   PubMed Web of Science ®Google Scholar
• Hogan M., Alvarado J. Studies on the human macula. Aging changes in Bruch's membrane. Arch Ophthalmol 1967; 77: 410–20
   PubMedGoogle Scholar
• Sarks S. H. Ageing and degeneration in the macular region: a clinico‐pathological study. Br J Ophthalmol 1976; 60: 324–41
   PubMed Web of Science ®Google Scholar
• Green W. R., McDonnell P. J., Yeo J. H. Pathologic features of senile macular degeneration. Ophthalmology 1985; 92: 615–27
   PubMed Web of Science ®Google Scholar
• Feeney‐Burns L., Ellersieck M. Age‐related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol 1985; 100: 686–97
   PubMed Web of Science ®Google Scholar
• Grindle C., Marshall J. Ageing changes in Bruch's membrane and their functional implications. Trans Ophthal Soc UK 1978; 98: 172–5
   PubMedGoogle Scholar
• Pauleikhoff D., Sheraidah G., Marshall J., Bird A., Wessing A. Biochemical and histochemical analysis of age related lipid deposits in Bruch's membrane. Ophthalmologe 1994; 91: 730–4
   PubMedGoogle Scholar
• Handa J. T., Verzijl N., Matsunaga H., Aotaki‐Keen A., Lutty G. A., te Koppele J. M., et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 1999; 40: 775–9
   PubMed Web of Science ®Google Scholar
• Curcio C., Millican C., Bailey T., Kruth H. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42: 265–74
   PubMed Web of Science ®Google Scholar
• Kamei M., Hollyfield J. TIMP‐3 in Bruch's membrane: changes during aging and in age‐related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 2367–75
   PubMed Web of Science ®Google Scholar
• Newsome D., Huh W., Green W. Bruch's membrane age‐related changes vary by region. Curr Eye Res 1987; 6: 1211–21
   PubMed Web of Science ®Google Scholar
• Ishibashi T., Murata T., Hangai M., Nagai R., Horiuchi S., Lopez P., et al. Advanced glycation end products in age‐related macular degeneration. Arch Ophthalmol 1998; 116: 1629–32
   PubMedGoogle Scholar
• Hewitt A., Nakazawa K., Newsome D. Analysis of newly synthesized Bruch's membrane proteoglycans. Invest Ophthalmol Vis Sci 1989; 30: 478–86
   PubMed Web of Science ®Google Scholar
• Karwatowski W., Jeffries T., Duance V., Albon J., Bailey A., Easty D. Preparation of Bruch's membrane and analysis of the age‐related changes in the structural collagens. Br J Ophthalmol 1995; 79: 944–52
   PubMed Web of Science ®Google Scholar
• Haimovici R., Gantz D. L., Rumelt S., Freddo T. F., Small D. M. The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci 2001; 42: 1592–9
   PubMed Web of Science ®Google Scholar
• Li C. M., Chung B. H., Presley J. B., Malek G., Zhang X., Dashti N., et al. Lipoprotein‐like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci 2005; 46: 2576–86
   PubMed Web of Science ®Google Scholar
• Starita C., Hussain A., Pagliarini S., Marshall J. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res 1996; 62: 565–72
   PubMed Web of Science ®Google Scholar
• Moore D., Clover G. The effect of age on the macromolecuar permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42: 2970–5
   PubMed Web of Science ®Google Scholar
• Hussain A., Rowe L., Marshall J. Age‐related alterations in the diffusional transport of amino acids across the human Bruch's‐choroid complex. J Opt Soc Am A Opt Image Sci Vis 2002; 19: 166–72
   Web of Science ®Google Scholar
• Moore D., Hussain A., Marshall J. Age‐related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci 1995; 36: 1290–7
   PubMed Web of Science ®Google Scholar
• Chong N. H., Keonin J., Luthert P. J., Frennesson C. I., Weingeist D. M., Wolf R. L., et al. Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age‐related macular degeneration. Am J Pathol 2005; 166: 241–51
   PubMed Web of Science ®Google Scholar
• Nackman G., Karkowski F., Halpern V., Gaetz H., Tilson M. Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery 1997; 122: 39–44
   PubMed Web of Science ®Google Scholar
• Kamisato S., Uemura Y., Takami N., Okamoto K. Involvement of intracellular cyclic GMP and cyclic GMP‐dependent protein kinase in alpha‐elastin‐induced macrophage chemotaxis. J Biochem (Tokyo) 1997; 121: 862–7
   Google Scholar
• Marshall J., Hussain A., Starita C., Moore D., Patmore A. Aging and Bruch's membrane. The Retinal Pigment Epithelium, M Marmor, T Wolfensberger. Oxford University Press, New York 1998; 669–92
   Google Scholar
• Holz F., Sheraiadah G., Pauleikhoff D., Marshall J., Bird A. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol 1994; 112: 402–6
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D., Harper C., Marshall J., Bird A. Aging changes in Bruch's membrane. Ophthalmology 1990; 97: 171–8
   PubMed Web of Science ®Google Scholar
• Anderson D., Ozaki S., Nealon M., Neitz J., Mullins R., Hageman G., et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: Implications for the process of drusen formation. Am J Ophthalmol 2001; 131: 767–81
   PubMed Web of Science ®Google Scholar
• Farkas T., Sylvester V., Archer D., Altona M. The histochemistry of drusen. Am J Ophthalmol 1971; 71: 1206–15
   PubMedGoogle Scholar
• Green W. R., Enger C. Age‐related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 1993; 100: 1519–35
   PubMed Web of Science ®Google Scholar
• Kliffen M., van der Schaft T. L., Mooy C. M., de Jong P. T. Morphologic changes in age‐related maculopathy. Microsc Res Tech 1997; 36: 106–22
   PubMed Web of Science ®Google Scholar
• Feher J., Valu L. [On the structure of Bruch's membrane]. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1967; 173: 162–7
   Google Scholar
• Loffler K. U., Lee W. R. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol 1986; 224: 493–501
   PubMed Web of Science ®Google Scholar
• van der Schaft T. L., de Bruijn W. C., Mooy C. M., Ketelaars D. A., de Jong P. T. Is basal laminar deposit unique for age‐related macular degeneration? [see comments]. Arch Ophthalmol 1991; 109: 420–5
   Google Scholar
• van der Schaft T., Mooy C., de Bruijn W., Oron F., Mulder P., de Jong P. Histological features of age‐related macular degeneration. A statistical analysis. Ophthalmology 1992; 99: 278–86
   PubMed Web of Science ®Google Scholar
• Spraul C. W., Lang G. E., Grossniklaus H. E. Morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in eyes with age‐related macular degeneration [see comments]. Invest Ophthalmol Vis Sci 1996; 37: 2724–35
   PubMed Web of Science ®Google Scholar
• Milam A. H., Curcio C. A., Cideciyan A. V., Saxena S., John S. K., Kruth H. S., et al. Dominant late‐onset retinal degeneration with regional variation of sub‐retinal pigment epithelium deposits, retinal function, and photoreceptor degeneration. Ophthalmology 2000; 107: 2256–66
   PubMed Web of Science ®Google Scholar
• Kliffen M., Mooy C. M., Luider T. M., Huijmans J. G., Kerkvliet S., de Jong P. T. Identification of glycosaminoglycans in age‐related macular deposits. Arch Ophthalmol 1996; 114: 1009–14
   Google Scholar
• Kliffen M., Mooy C. M., Luider T. M., de Jong P. T. Analysis of carbohydrate structures in basal laminar deposit in aging human maculae. Invest Ophthalmol Vis Sci 1994; 35: 2901–5
   Google Scholar
• van der Schaft T., Mooy C., de Bruijn W., Bosman F., de Jong P. Immunohistochemical light and electron microscopy of basal laminar deposit. Graefes Arch Clin Exp Ophthalmol 1994; 232: 40–6
   PubMed Web of Science ®Google Scholar
• Knupp C., Amin S., Munro P., Luthert P., Squire J. Collagen VI assemblies in age‐related macular degeneration. J Struct Biol 2002; 139: 181–9
   Google Scholar
• Curcio C. A., Presley J. B., Millican C. L., Medeiros N. E. Basal deposits and drusen in eyes with age‐related maculopathy: evidence for solid lipid particles. Exp Eye Res 2005; 80: 761–75
   PubMed Web of Science ®Google Scholar
• Sarks S., Van Driel D., Maxwell L., Killingsworth M. Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K 1980; 100: 414–22
   PubMedGoogle Scholar
• Okubo A., Rosa R., Bunce C., Alexander R., Fan J., Bird A., et al. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci 1999; 40: 443–9
   PubMed Web of Science ®Google Scholar
• Hogan M. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol 1972; 76: 64–80
   PubMedGoogle Scholar
• Bird A. Pathophysiology of AMD. Age‐related macular degeneration: principles and practice, G. R Hampton, P. T Nelsen. Raven Press, New York 1992, Chapter 3
   Google Scholar
• Dorey C., Wu G., Ebenstein D. Cell loss in the aging retina: Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 1989; 30: 1691–9
   PubMed Web of Science ®Google Scholar
• Bird A. C. Bruch's membrane change with age. Br J Ophthalmol 1992; 76: 166–8
   PubMedGoogle Scholar
• Katz M. L., Robison W. G., Jr. Age‐related changes in the retinal pigment epithelium of pigmented rats. Exp Eye Res 1984; 38: 137–51
   PubMed Web of Science ®Google Scholar
• Feeney‐Burns L., Hilderbrand E., Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial and peripheral cells. Invest Ophthalmol Vis Sci 1984; 25: 195–200
   PubMed Web of Science ®Google Scholar
• Wing G., Blanchard G., Weiter J. Topography and age relationship of lipofuscin concentration in the RPE. Invest Ophthalmol Vis Sci 1978; 7: 601–7
   Google Scholar
• Rozanowska M., Jarvis‐Evans J., Korytowski W., Boulton M. E., Burke J. M., Sarna T. Blue light‐induced reactivity of retinal age pigment. In vitro generation of oxygen‐reactive species. J Biol Chem 1995; 270: 18825–30
   PubMed Web of Science ®Google Scholar
• Holz F., Bellman C., Staudt S., Schutt F., Volcker H. Fundus autofluorescence and development of geographic atrophy in age‐related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42: 1051–6
   PubMed Web of Science ®Google Scholar
• Katz M. L. Potential role of retinal pigment epithelial lipofuscin accumulation in age‐related macular degeneration. Arch Gerontol Geriatr 2002; 34: 359–70
   PubMed Web of Science ®Google Scholar
• Sparrow J. R., Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005; 80: 595–606
   PubMed Web of Science ®Google Scholar
• Ramrattan R., van der Schaft T., Mooy C., de Bruijn W., Mulder P., de Jong P. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 1994; 35: 2857–64
   PubMed Web of Science ®Google Scholar
• McLeod D. S., Taomoto M., Otsuji T., Green W. R., Sunness J. S., Lutty G. A. Quantifying changes in RPE and choroidal vasculature in eyes with age‐related macular degeneration. Invest Ophthalmol Vis Sci 2002 Jun; 43: 1986–93
   PubMed Web of Science ®Google Scholar
• Midena E., Segato T., Blarzino M. C., Degli Angeli C. Macular drusen and the sensitivity of the central visual field. Doc Ophthalmol 1994; 88: 179–85
   PubMed Web of Science ®Google Scholar
• Curcio C., Medeiros N., Millican C. Photoreceptor loss in age‐related macular degeneration. Invest Ophthalmol Vis Sci 1996; 37: 1236–49
   PubMed Web of Science ®Google Scholar
• Jackson G. R., Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 2003; 21: 709–28
   PubMed Web of Science ®Google Scholar
• Li J., Tso M. O., Lam T. T. Reduced amplitude and delayed latency in foveal response of multifocal electroretinogram in early age related macular degeneration. Br J Ophthalmol 2001; 85: 287–90
   PubMed Web of Science ®Google Scholar
• Owsley C., Jackson G. R., Cideciyan A. V., Huang Y., Fine S. L., Ho A. C., et al. Psychophysical evidence for rod vulnerability in age‐related macular degeneration. Invest Ophthalmol Vis Sci 2000; 41: 267–73
   PubMed Web of Science ®Google Scholar
• Jackson G. R., Owsley C., Curcio C. A. Photoreceptor degeneration and dysfunction in aging and age‐related maculopathy. Ageing Res Rev 2002; 1: 381–96
   PubMed Web of Science ®Google Scholar
• Owsley C., Jackson G. R., White M., Feist R., Edwards D. Delays in rod‐mediated dark adaptation in early age‐related maculopathy. Ophthalmology 2001; 108: 1196–202
   PubMed Web of Science ®Google Scholar
• Jackson G. R., McGwin G., Jr., Phillips J. M., Klein R., Owsley C. Impact of aging and age‐related maculopathy on activation of the a‐wave of the rod‐mediated electroretinogram. Invest Ophthalmol Vis Sci 2004; 45: 3271–8
   PubMed Web of Science ®Google Scholar
• Owsley C., McGwin G., Jackson G. R., Heimburger D. C., Piyathilake C. J., Klein R., et al. Effect of short‐term, high‐dose retinol on dark adaptation in aging and early age‐related maculopathy. Invest Ophthalmol Vis Sci 2006; 47: 1310–8
   PubMed Web of Science ®Google Scholar
• Stangos N., Voutas S., Topouzis F., Karampatakis V. Contrast sensitivity evaluation in eyes predisposed to age‐related macular degeneration and presenting normal visual acuity. Ophthalmologica 1995; 209: 194–8
   PubMed Web of Science ®Google Scholar
• Sunness J., Massof R., Johnson M., Bressler N., Bressler S., Fine S. Diminished foveal sensitivity may predict the development of advanced age‐related macular degeneration. Ophthalmology 1989; 96: 375–81
   Web of Science ®Google Scholar
• Kleiner R. C., Enger C., Alexander M. F., Fine S. L. Contrast sensitivity in age‐related macular degeneration. Arch Ophthalmol 1988; 106: 55–7
   PubMedGoogle Scholar
• Sandberg M. A., Gaudio A. R. Slow photostress recovery and disease severity in age‐related macular degeneration. Retina 1995; 15: 407–12
   PubMed Web of Science ®Google Scholar
• Eisner A., Klein M. L., Zilis J. D., Watkins M. D. Visual function and the subsequent development of exudative age‐related macular degeneration. Invest Ophthalmol Vis Sci 1992; 33: 3091–102
   PubMed Web of Science ®Google Scholar
• Eisner A., Stoumbos V. D., Klein M. L., Fleming S. A. Relations between fundus appearance and function. Eyes whose fellow eye has exudative age‐related macular degeneration. Invest Ophthalmol Vis Sci 1991; 32: 8–20
   PubMed Web of Science ®Google Scholar
• Johnson P. T., Brown M. N., Pulliam B. C., Anderson D. H., Johnson L. V. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci 2005; 46: 4788–95
   PubMed Web of Science ®Google Scholar
• Johnson P. T., Lewis G. P., Talaga K. C., Brown M. N., Kappel P. J., Fisher S. K., et al. Drusen‐associated degeneration in the retina. Invest Ophthalmol Vis Sci 2003; 44: 4481–8
   PubMed Web of Science ®Google Scholar
• Hageman G. S., Luthert P. J., Victor Chong N. H., Johnson L. V., Anderson D. H., Mullins R. F. An integrated hypothesis that considers drusen as biomarkers of immune‐mediated processes at the rpe‐bruch's membrane interface in aging and age‐related macular degeneration. Prog Retin Eye Res 2001; 20: 705–32
   PubMed Web of Science ®Google Scholar
• Anderson D., Mullins R., Hageman G., Johnson L. V. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411–31
   PubMed Web of Science ®Google Scholar
• Killingsworth M., Sarks J., Sarks S. Macrophages related to Bruch's membrane in age‐related macular degeneration. Eye 1990; 4: 613–21
   PubMed Web of Science ®Google Scholar
• Penfold P. L., Madigan M. C., Gillies M. C., Provis J. M. Immunological and Aetiological Aspects of Macular Degeneration. Progress in Retinal Research. Elsevier Science Ltd, London 2001; 385–414
   Google Scholar
• Heriot W., Henkind P., Bellhorn R., Burns M. Choroidal neovascularization can digest Bruch's membrane. A prior break is not essential. Ophthalmology 1984; 91: 1603–8
   PubMed Web of Science ®Google Scholar
• Penfold P., Killingsworth M., Sarks S. An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch's membrane. Aust J Ophthalmol 1984; 12: 23–31
   PubMedGoogle Scholar
• Dastgheib K., Green W. Granulomatous reaction to Bruch's membrane in age‐related macular degeneration. Arch Ophthalmol 1994; 112: 813–8
   PubMedGoogle Scholar
• Hageman G., Mullins R., Russell S., Johnson L., Anderson D. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J 1999; 13: 477–84
   PubMed Web of Science ®Google Scholar
• Mullins R. F., Russell S. R., Anderson D. H., Hageman G. S. Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000; 14: 835–46
   PubMed Web of Science ®Google Scholar
• Johnson L., Ozaki S., Staples M., Erickson P., Anderson D. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000; 70: 441–9
   PubMed Web of Science ®Google Scholar
• Johnson L., Leitner W., Staples M., Anderson D. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 2001; 73: 887–96
   PubMed Web of Science ®Google Scholar
• Mullins R. F., Johnson L. V., Anderson D. H., Hageman G. S. Characterization of drusen‐associated glycoconjugates. Ophthalmology 1997; 104: 288–94
   PubMed Web of Science ®Google Scholar
• Russell S. R., Mullins R. F., Schneider B. L., Hageman G. S. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age‐related macular degeneration. Am J Ophthalmol 2000; 129: 205–14
   PubMed Web of Science ®Google Scholar
• Mullins R. F., Aptsiauri N., Hageman G. S. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 2001; 15((Pt 3))390–5
   Google Scholar
• Johnson L. V., Leitner W. P., Rivest A. J., Staples M. K., Radeke M. J., Anderson D. H. The Alzheimer's A beta‐peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age‐related macular degeneration. Proc Natl Acad Sci U S A 2002; 99: 11830–5
   PubMed Web of Science ®Google Scholar
• Malek G., Li C. M., Guidry C., Medeiros N. E., Curcio C. A. Apolipoprotein B in cholesterol‐containing drusen and basal deposits of human eyes with age‐related maculopathy. Am J Pathol 2003; 162: 413–25
   PubMed Web of Science ®Google Scholar
• Anderson D., Talaga K., Rivest A., Barron E., Hageman G., Johnson L. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age‐related macular degeneration. Exp Eye Res 2004; 78: 243–56
   PubMed Web of Science ®Google Scholar
• Peto T., Lengyel I., Frederickson C., Vankuijk F. Zinc in Drusen. Invest Ophthalmol Vis Sci 2005; 46, E‐Abstract 3008
   Google Scholar
• Holers V. M. The complement system as a therapeutic target in autoimmunity. Clin Immunol 2003; 107: 140–51
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Locksley R. M. The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50–3
   PubMed Web of Science ®Google Scholar
• Mastellos D., Andronis C., Persidis A., Lambris J. D. Novel biological networks modulated by complement. Clin Immunol 2005; 115: 225–35
   PubMed Web of Science ®Google Scholar
• Mastellos D., Germenis A. E., Lambris J. D. Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Curr Drug Targets Inflamm Allergy 2005; 4): 125–7
   Google Scholar
• Walport M. J. Complement. Second of two parts. N Engl J Med 2001; 344: 1140–4
   PubMed Web of Science ®Google Scholar
• Walport M. J. Complement. First of two parts. N Engl J Med 2001; 344: 1058–66
   PubMed Web of Science ®Google Scholar
• Thurman J. M., Holers V. M. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305–10
   PubMed Web of Science ®Google Scholar
• Pio R., Martinez A., Unsworth E. J., Kowalak J. A., Bengoechea J. A., Zipfel P. F., et al. Complement factor H is a serum‐binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001; 276: 12292–300
   PubMed Web of Science ®Google Scholar
• Holers V. M., Thurman J. M. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol 2004; 41: 147–52
   PubMedGoogle Scholar
• Song W. C. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr Dir Autoimmun 2004; 7: 181–99
   Google Scholar
• Zipfel P. F., Heinen S., Jozsi M., Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97–106
   PubMed Web of Science ®Google Scholar
• Halstensen T. S., Mollnes T. E., Fausa O., Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 1989; 30: 361–6
   PubMedGoogle Scholar
• Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683–747
   PubMed Web of Science ®Google Scholar
• Lassmann H. Recent neuropathological findings in MS—implications for diagnosis and therapy. J Neurol 2004 Sep; 251(Suppl 4)IV2–5
   PubMedGoogle Scholar
• Neumann E., Barnum S. R., Tarner I. H., Echols J., Fleck M., Judex M., et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002; 46: 934–45
   PubMed Web of Science ®Google Scholar
• Tang S., Lui S. L., Lai K. N. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton) 2005; 10: 174–9
   PubMed Web of Science ®Google Scholar
• Turnberg D., Cook H. T. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens 2005; 14: 223–8
   Google Scholar
• Gerard N. P., Gerard C. Complement in allergy and asthma. Curr Opin Immunol 2002; 14: 705–8
   Google Scholar
• Rodriguez de Cordoba S., Esparza‐Gordillo J., Goicoechea de Jorge E., Lopez‐Trascasa M., Sanchez‐Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355–67
   PubMed Web of Science ®Google Scholar
• Pangburn M. K., Pangburn K. L., Koistinen V., Meri S., Sharma A. K. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol 2000; 164: 4742–51
   PubMed Web of Science ®Google Scholar
• Zipfel P. F. Complement factor H: physiology and pathophysiology. Semin Thromb Hemost 2001; 27: 191–9
   PubMed Web of Science ®Google Scholar
• Hageman G. S., Anderson D. H., Johnson L. V., Hancox L. S., Taiber A. J., Hardisty L. I., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age‐related macular degeneration. Proc Natl Acad Sci U S A 2005; 102: 7227–32
   PubMed Web of Science ®Google Scholar
• Johnson L. V., Talaga K. C., Rivest A. J., Staples M. K., Radeke M. J., Barron E., et al. Characterization of Beta Amyloid‐Containing Vesicles within Drusen. Invest Ophthalmol Vis Sci 2003; 44, E‐Abstract 4229
   Google Scholar
• Hageman G., Luthert P., Chong N., Johnson L., Anderson D., Mullins R. An integrated hypothesis that considers drusen as biomarkers of immune‐mediated processes at the RPE‐Bruch's membrane interface in aging and age‐related macular degeneration. Prog Retin Eye Res 2001; 20: 705–32
   PubMed Web of Science ®Google Scholar
• Miller D. M., Espinosa‐Heidmann D. G., Legra J., Dubovy S. R., Suner I. J., Sedmak D. D., et al. The association of prior cytomegalovirus infection with neovascular age‐related macular degeneration. Am J Ophthalmol 2004; 138: 323–8
   PubMed Web of Science ®Google Scholar
• Klein M., Mauldin W., Stoumbos V. Heredity and age‐related macular degeneration. Observations in monozygotic twins. Arch Ophthalmol 1994; 112: 932–7
   PubMedGoogle Scholar
• Heiba I., Elston R., Klein B., Klein R. Sibling correlations and segregation analysis of age‐related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 1994; 11: 51–67
   PubMed Web of Science ®Google Scholar
• Seddon J., Ajani U., Mitchell B. Familial aggregation of age‐related maculopathy. Am J Ophthalmol 1997; 123: 199–206
   PubMed Web of Science ®Google Scholar
• Meyers S. M., Greene T., Gutman F. A. A twin study of age‐related macular degeneration. Am J Ophthalmol 1995; 120: 757–66
   PubMed Web of Science ®Google Scholar
• Hammond C. J., Webster A. R., Snieder H., Bird A. C., Gilbert C. E., Spector T. D. Genetic influence on early age‐related maculopathy: a twin study. Ophthalmology 2002; 109: 730–6
   PubMed Web of Science ®Google Scholar
• Abecasis G. R., Yashar B. M., Zhao Y., Ghiasvand N. M., Zareparsi S., Branham K. E., et al. Age‐related macular degeneration: a high‐resolution genome scan for susceptibility loci in a population enriched for late‐stage disease. Am J Hum Genet 2004; 74: 482–94
   PubMed Web of Science ®Google Scholar
• Iyengar S. K., Song D., Klein B. E., Klein R., Schick J. H., Humphrey J., et al. Dissection of genomewide‐scan data in extended families reveals a major locus and oligogenic susceptibility for age‐related macular degeneration. Am J Hum Genet 2004; 74: 20–39
   PubMed Web of Science ®Google Scholar
• Klein M. L., Schultz D. W., Edwards A., Matise T. C., Rust K., Berselli C. B., et al. Age‐related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol 1998; 116: 1082–8
   PubMed Web of Science ®Google Scholar
• Majewski J., Schultz D. W., Weleber R. G., Schain M. B., Edwards A. O., Matise T. C., et al. Age‐related macular degeneration—a genome scan in extended families. Am J Hum Genet 2003; 73: 540–50
   PubMed Web of Science ®Google Scholar
• Schick J. H., Iyengar S. K., Klein B. E., Klein R., Reading K., Liptak R., et al. A whole‐genome screen of a quantitative trait of age‐related maculopathy in sibships from the Beaver Dam Eye Study. Am J Hum Genet 2003; 72: 1412–24
   PubMed Web of Science ®Google Scholar
• Seddon J. M., Santangelo S. L., Book K., Chong S., Cote J. A genomewide scan for age‐related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet 2003; 73: 780–90
   PubMed Web of Science ®Google Scholar
• Weeks D. E., Conley Y. P., Mah T. S., Paul T. O., Morse L., Ngo‐Chang J., et al. A full genome scan for age‐related maculopathy. Hum Mol Genet 2000; 9: 1329–49
   PubMed Web of Science ®Google Scholar
• Weeks D. E., Conley Y. P., Tsai H. J., Mah T. S., Rosenfeld P. J., Paul T. O., et al. Age‐related maculopathy: an expanded genome‐wide scan with evidence of susceptibility loci within the 1q31 and 17q25 regions. Am J Ophthalmol 2001; 132: 682–92
   PubMed Web of Science ®Google Scholar
• Weeks D. E., Conley Y. P., Tsai H. J., Mah T. S., Schmidt S., Postel E. A., et al. Age‐Related Maculopathy: A Genomewide Scan with Continued Evidence of Susceptibility Loci within the 1q31, 10q26, and 17q25 Regions. Am J Hum Genet 2004; 75((2))174–89
   PubMed Web of Science ®Google Scholar
• Fisher S. A., Abecasis G. R., Yashar B. M., Zareparsi S., Swaroop A., Iyengar S. K., et al. Meta‐analysis of genome scans of age‐related macular degeneration. Hum Mol Genet 2005; 14: 2257–64
   PubMed Web of Science ®Google Scholar
• Schultz D., Klein M., Humpert A., Luzier C., Persun V., Schain M., et al. Analysis of the ARMD1 locus: Evidence that a mutation in HEMICENTIN‐1 is associated with age‐related macular degeneration in a large family. Hum Mol Genet 2003; 12: 3315–23
   PubMed Web of Science ®Google Scholar
• Conley Y. P., Thalamuthu A., Jakobsdottir J., Weeks D. E., Mah T., Ferrell R. E., et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age‐related maculopathy. Hum Mol Genet 2005; 14: 1991–2002
   PubMed Web of Science ®Google Scholar
• Haines J. L., Schnetz‐Boutaud N., Schmidt S., Scott W. K., Agarwal A., Postel E. A., et al. Functional candidate genes in age‐related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006; 47: 329–35
   PubMed Web of Science ®Google Scholar
• Stone E. M., Braun T. A., Russell S. R., Kuehn M. H., Lotery A. J., Moore P. A., et al. Missense variations in the fibulin 5 gene and age‐related macular degeneration. N Engl J Med 2004; 351: 346–53
   PubMed Web of Science ®Google Scholar
• Zareparsi S., Buraczynska M., Branham K. E., Shah S., Eng D., Li M., et al. Toll‐like receptor 4 variant D299G is associated with susceptibility to age‐related macular degeneration. Hum Mol Genet 2005; 14: 1449–55
   PubMed Web of Science ®Google Scholar
• Souied E. H., Benlian P., Amouyel P., Feingold J., Lagarde J. P., Munnich A., et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age‐related macular degeneration. Am J Ophthalmol 1998; 125: 353–9
   PubMed Web of Science ®Google Scholar
• Klaver C. C., Kliffen M., van Duijn C. M., Hofman A., Cruts M., Grobbee D. E., et al. Genetic association of apolipoprotein E with age‐related macular degeneration. Am J Hum Genet 1998; 63: 200–6
   PubMed Web of Science ®Google Scholar
• Baird P. N., Guida E., Chu D. T., Vu H. T., Guymer R. H. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age‐related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45: 1311–5
   PubMed Web of Science ®Google Scholar
• Allikmets R., Shroyer N., Singh N., Seddon J., Lewis R., Bernstein P., et al. Mutation of the Stargardt disease gene (ABCR) in age‐related macular degeneration. Science 1997; 277: 1805–7
   PubMed Web of Science ®Google Scholar
• Klein R. J., Zeiss C., Chew E. Y., Tsai J. Y., Sackler R. S., Haynes C., et al. Complement factor H polymorphism in age‐related macular degeneration. Science 2005; 15(308)385–9
   Google Scholar
• Edwards A. O., Ritter R., 3rd., Abel K. J., Manning A., Panhuysen C., Farrer L. A. Complement factor H polymorphism and age‐related macular degeneration. Science 2005; 308: 421–4
   PubMed Web of Science ®Google Scholar
• Haines J. L., Hauser M. A., Schmidt S., Scott W. K., Olson L. M., Gallins P., et al. Complement factor H variant increases the risk of age‐related macular degeneration. Science 2005; 308: 419–21
   PubMed Web of Science ®Google Scholar
• Zareparsi S., Branham K. E., Li M., Shah S., Klein R. J., Ott J., et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age‐related macular degeneration. Am J Hum Genet 2005; 77: 149–53
   PubMed Web of Science ®Google Scholar
• Magnusson K. P., Duan S., Sigurdsson H., Petursson H., Yang Z., Zhao Y., et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3: e5
   PubMed Web of Science ®Google Scholar
• Sepp T., Khan J. C., Thurlby D. A., Shahid H., Clayton D. G., Moore A. T., et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 2006; 47: 536–40
   PubMed Web of Science ®Google Scholar
• Souied E. H., Leveziel N., Richard F., Dragon‐Durey M. A., Coscas G., Soubrane G., et al. Y402H complement factor H polymorphism associated with exudative age‐related macular degeneration in the French population. Mol Vis 2005; 11: 1135–40
   PubMed Web of Science ®Google Scholar
• Okamoto H., Umeda S., Obazawa M., Minami M., Noda T., Mizota A., et al. Complement factor H polymorphisms in Japanese population with age‐related macular degeneration. Mol Vis 2006; 12: 156–8
   PubMed Web of Science ®Google Scholar
• Gold B., Merriam J. E., Zernant J., Hancox L. S., Taiber A. J., Gehrs K., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age‐related macular degeneration. Nat Genet 2006; 38: 458–62
   PubMed Web of Science ®Google Scholar
• Lokki M. L., Koskimies S. A. Allelic differences in hemolytic activity and protein concentration of BF molecules are found in association with particular HLA haplotypes. Immunogenetics 1991; 34: 242–6
   PubMed Web of Science ®Google Scholar
• Jakobsdottir J., Conley Y. P., Weeks D. E., Mah T. S., Ferrell R. E., Gorin M. B. Susceptibility genes for age‐related maculopathy on chromosome 10q26. Am J Hum Genet 2005; 77: 389–407
   PubMed Web of Science ®Google Scholar
• Rivera A., Fisher S. A., Fritsche L. G., Keilhauer C. N., Lichtner P., Meitinger T., et al. Hypothetical LOC387715 is a second major susceptibility gene for age‐related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14: 3227–36
   PubMed Web of Science ®Google Scholar
• Schmidt S., Hauser M. A., Scott W. K., Postel E. A., Agarwal A., Gallins P., et al. Cigarette smoking strongly modifies the association of LOC387715 and age‐related macular degeneration. Am J Hum Genet 2006; 78: 852–64
   PubMed Web of Science ®Google Scholar
• Saunders R. E., Goodship T. H., Zipfel P. F., Perkins S. J. An interactive web database of factor H‐associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease‐associated mutations. Hum Mutat 2006; 27: 21–30
   PubMed Web of Science ®Google Scholar
• Heinen S., Sanchez‐Corral P., Jackson M. S., Strain L., Goodship J. A., Kemp E. J., et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27: 292–3
   PubMedGoogle Scholar
• Warwicker P., Goodship T. H., Donne R. L., Pirson Y., Nicholls A., Ward R. M., et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836–44
   PubMed Web of Science ®Google Scholar
• Esparza‐Gordillo J., Goicoechea de Jorge E., Buil A., Carreras Berges L., Lopez‐Trascasa M., Sanchez‐Corral P., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703–12
   PubMed Web of Science ®Google Scholar
• Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C‐257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385–95
   PubMed Web of Science ®Google Scholar
• Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267–79
   PubMed Web of Science ®Google Scholar
• Atkinson J. P., Liszewski M. K., Richards A., Kavanagh D., Moulton E. A. Hemolytic uremic syndrome: an example of insufficient complement regulation on self‐tissue. Ann N Y Acad Sci 2005; 1056: 144–52
   Google Scholar
• Abrera‐Abeleda M. A., Nishimura C., Smith J. L., Sethi S., McRae J. L., Murphy B. F., et al. Variations in the Complement Regulatory Genes Factor H (CFH) and Factor H Related 5 (CFHR5) are Associated with Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease). J Med Genet 2006; 43: 582–9
   PubMed Web of Science ®Google Scholar
• Appel G. B., Cook H. T., Hageman G., Jennette J. C., Kashgarian M., Kirschfink M., et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392–403
   PubMed Web of Science ®Google Scholar
• Robman L., Mahdi O., McCarty C., Dimitrov P., Tikellis G., McNeil J., et al. Exposure to Chlamydia pneumoniae infection and progression of age‐related macular degeneration. Am J Epidemiol 2005; 161: 1013–9
   PubMed Web of Science ®Google Scholar
• Erkkila H., Raitta C., Niemi K. Ocular findings in four siblings with pseudoxanthoma elasticum. Acta Ophthalmol (Copenh) 1983; 61: 589–99
   Google Scholar
• Zee R. Y., Diehl K. A., Ridker P. M. Complement factor H Y402H gene polymorphism, C‐reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case‐control study. Atherosclerosis 2006; 187: 332–5
   PubMedGoogle Scholar